Genetically determined ABO blood group, secretor status, Lewis antigens, and panNEN risk
Endocrine-Related Cancer · 2026
DOI: 10.1530/erc-26-0286 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2026. Verfasst von Samuel O Antwi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic , Jacksonville, Florida, USA. Hauptthemen laut MEDLINE: ABO Blood-Group System, Lewis Blood Group Antigens, Pancreatic Neoplasms, Fucosyltransferases. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pancreatic neuroendocrine neoplasms (panNENs) are rare endocrine malignancies with poorly defined risk factors, in contrast to the more common pancreatic ductal adenocarcinoma (PDAC), for which non-O ABO blood group is a well-established susceptibility marker. To determine whether ABO and related glycosylation markers associated with PDAC risk extend to panNENs, we conducted a case–control study of 1,059 pathologically confirmed panNEN cases from the Mayo Clinic Biospecimen Resource for Pancreas Research and 33,018 cancer-free controls from the Mayo ClinicBiobank. Using germline genotype data, we inferred ABO blood group, FUT2-defined secretor status, and FUT3-defined Lewis antigen phenotypes and calculated odds ratios (ORs) and 95% confidence intervals (CIs) using logistic regression adjusted for age, sex, and ancestry principal components. ABO blood group was not associated with panNEN risk: compared with blood group O, the OR for non-O was 0.98 (95% CI: 0.87–1.11), with similarly null findings for blood groups A, B, and AB individually. Secretor status (OR = 0.98, 95% CI: 0.84–1.14) and Lewis-positive phenotypes (OR = 0.91, 95% CI: 0.75–1.13) were also not associated with risk, and no interactions were observed between blood group and secretor status or Lewis antigen phenotypes. Given our high statistical power to detect previously reported PDAC effect sizes for non-O blood group, these null findings are informative, indicating that the ABO-linked glycosylation, inflammatory, and host–microbe interaction pathways implicated in PDAC are unlikely to be major determinants of panNEN susceptibility. This study therefore sharpens the etiologic distinction between pancreatic exocrine and neuroendocrine cancers, redirecting panNEN research beyond PDAC paradigms toward alternative mechanisms of endocrine tumorigenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic , Jacksonville, Florida, USA.
- Department of Quantitative Health Sciences, Mayo Clinic , Rochester, Minnesota, USA.
- Department of Medical Oncology, Mayo Clinic , Rochester, Minnesota, USA.
- OSF HealthCare Cancer Institute, University of Illinois , Peoria, Illinois, USA.
- Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic , Rochester, Minnesota, USA.
ORCID-Profile: Samuel O Antwi
Zitieren
APA
Antwi, S. O., Carlson, E. E., Rabe, K. G., Koganti, T., Bamlet, W. R., MAYO-RGC Project Generation, Regeneron Genetics Center, Halfdanarson, T. R., McWilliams, R. R., Wangensteen, K. J., & Oberg, A. L. (2026). Genetically determined ABO blood group, secretor status, Lewis antigens, and panNEN risk. Endocrine-Related Cancer. https://doi.org/10.1530/erc-26-0286
Vancouver
Antwi SO, Carlson EE, Rabe KG, Koganti T, Bamlet WR, MAYO-RGC Project Generation, et al. Genetically determined ABO blood group, secretor status, Lewis antigens, and panNEN risk. Endocrine-Related Cancer. 2026. doi:10.1530/erc-26-0286
BibTeX
@article{Antwi2026,
author = {Antwi, Samuel O and Carlson, Erin E and Rabe, Kari G and Koganti, Teja and Bamlet, William R and MAYO-RGC Project Generation, MAYO-RGC Project Generation and Regeneron Genetics Center, Regeneron Genetics Center and Halfdanarson, Thorvardur R and McWilliams, Robert R and Wangensteen, Kirk J and Oberg, Ann L},
title = {Genetically determined ABO blood group, secretor status, Lewis antigens, and panNEN risk},
journal = {Endocrine-Related Cancer},
year = {2026},
doi = {10.1530/erc-26-0286}
}
EUVIMED